Skip to main navigation Skip to search Skip to main content

Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study

  • Andrew Ip
  • , Jaeil Ahn
  • , Yizhao Zhou
  • , Andre H. Goy
  • , Eric Hansen
  • , Andrew L. Pecora
  • , Brittany A. Sinclaire
  • , Urszula Bednarz
  • , Michael Marafelias
  • , Ihor S. Sawczuk
  • , Joseph P. Underwood
  • , David M. Walker
  • , Rajiv Prasad
  • , Robert L. Sweeney
  • , Marie G. Ponce
  • , Samuel La Capra
  • , Frank J. Cunningham
  • , Arthur G. Calise
  • , Bradley L. Pulver
  • , Dominic Ruocco
  • Greggory E. Mojares, Michael P. Eagan, Kristy L. Ziontz, Paul Mastrokyriakos, Stuart L. Goldberg
  • Georgetown University
  • COTA
  • HACKENSACK UNIVERSITY MEDICAL CENTER
  • Bayshore Medical Center
  • Jersey Shore University Medical Center
  • Solaris Health System
  • Hackensack Meridian Health Mountainside Medical Center
  • Ocean Medical Center
  • Palisades Medical Center
  • Pascack Valley Medical Center
  • Hackensack Meridian Health
  • Riverview Medical Center
  • Southern Ocean Medical Center

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Background: Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting. Methods: We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching. Results: Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available. Conclusions: In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.

Original languageEnglish
Article number72
JournalBMC Infectious Diseases
Volume21
Issue number1
DOIs
StatePublished - Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19
  • Hydroxychloroquine
  • Outpatient

Fingerprint

Dive into the research topics of 'Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study'. Together they form a unique fingerprint.

Cite this